Contract award notice
Results of the procurement procedure
Section I: Contracting
authority
I.1) Name and addresses
The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health)
2nd Floor, Rutland House
Runcorn
WA7 2ES
UK
E-mail: gemma.tomlinson1@nhs.net
NUTS: UK
Internet address(es)
Main address: https://cmu.bravosolution.co.uk
Address of the buyer profile: https://cmu.bravosolution.co.uk
I.4) Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
NHS National Pharmaceuticals — Wave 10c.
Reference number: CM/PHG/15/5466
II.1.2) Main CPV code
33600000
II.1.3) Type of contract
Supplies
II.1.4) Short description
Invitation to offer for NHS National Pharmaceuticals — Wave 10c
Offer reference number: CM/PHG/15/5466 Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 40 months.
Potential periods of call-offs under the framework agreement: Oral Products: All Regions 1.7./2017 to 28.2.2019 (20 months) Hospital Only Products: Central and South West (CESW) 1.7.2017 to 30.6.2018 (12 months); North West and Eastern and North London (NWLN) 1.7.2017 to 30.6.2018 (12 months) and South East and South London and North East and Yorkshire (LSNE) 1.7.2017 to 30.6.2018 (12 months).
II.1.6) Information about lots
This contract is divided into lots:
Yes
II.1.7) Total value of the procurement
Value excluding VAT:
240 000 000.00
GBP
II.2) Description
Lot No: 01
II.2.1) Title
Wave 10c — Oral Products: All Regions
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Please refer to Document 10 in the ITO Documents for the list of Purchasing Points.
II.2.4) Description of the procurement
NHS National Pharmaceuticals — Wave 10c.
Offer reference number: CM/PHG/15/5466.
Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 40 months.
Potential periods of call-offs under the framework agreement: Oral Products: All Regions 1.7.2017 to 28.2.2019 (20 months).
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: In descending order
Cost criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the Invitation to Tender or to negotiate or in the descriptive document.
/ Weighting: N/A
II.2.11) Information about options
Options:
Yes
Description of options:
This framework agreement has the option to extend for a period of up to 20 months.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 02
II.2.1) Title
Wave 10c — Hospital Only Products: CESW
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Please refer to Document 10 in the ITO Documents for the list of Purchasing Points.
II.2.4) Description of the procurement
NHS National Pharmaceuticals — Wave 10c.
Offer reference number: CM/PHG/15/5466.
Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 24 months.
Potential periods of call-offs under the framework agreement: Hospital Only Products: Central and South West (CESW) 1.7.2017 to 30.6.2018 (12 months).
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: In descending order
Cost criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the Invitation to Tender or to negotiate or in the descriptive document.
/ Weighting: N/A
II.2.11) Information about options
Options:
Yes
Description of options:
This framework agreement has the option to extend for a period of up to 12 months.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 03
II.2.1) Title
Wave 10c — Hospital Only Products: LSNE
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Please refer to Document 10 in the ITO Documents for the list of Purchasing Points.
II.2.4) Description of the procurement
NHS National Pharmaceuticals — Wave 10c.
Offer reference number: CM/PHG/15/5466.
Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 24 months.
Potential periods of call-offs under the framework agreement: Hospital Only Products: South East and South London and North East and Yorkshire (LSNE) 1.7.2017 to 30.6.2018 (12 months).
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: In descending order
Cost criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the Invitation to Tender or to negotiate or in the descriptive document.
/ Weighting: N/A
II.2.11) Information about options
Options:
Yes
Description of options:
This framework agreement has the option to extend for a period of up to 12 months.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 04
II.2.1) Title
Wave 10c — Hospital Only Products: NWLN
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Please refer to Document 10 in the ITO Documents for the list of Purchasing Points.
II.2.4) Description of the procurement
NHS National Pharmaceuticals — Wave 10c.
Offer reference number: CM/PHG/15/5466.
Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 24 months.
Potential periods of call-offs under the framework agreement: Hospital Only Products: North West and Eastern and North London (NWLN) 1.7.2017 to 30.6.2018 (12 months).
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: In descending order
Cost criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the Invitation to Tender or to negotiate or in the descriptive document.
/ Weighting: N/A
II.2.11) Information about options
Options:
Yes
Description of options:
This framework agreement has the option to extend for a period of up to 12 months.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2016/S 243-443082
Section V: Award of contract
Lot No: All Lots
Contract No: CM/PHG/15/5466
Title: NHS National Pharmaceuticals — Wave 10c
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
27/04/2017
V.2.2) Information about tenders
Number of tenders received: 92
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Please see section VI.3)
Please see section VI.3)
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 240 000 000.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
Please see list of awarded suppliers (including SME status) at the following website: https://www.gov.uk/contracts-finder
VI.4) Procedures for review
VI.4.1) Review body
The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health)
Runcorn
UK
VI.5) Date of dispatch of this notice
26/05/2017